Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Cure8 research brief
Why This Matters
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
Who Should Pay Attention
Adults with IBD on biologics or oral small molecules, clinicians who prescribe or monitor advanced therapies, adherence researchers, and clinic care coordinators.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study followed 342 IBD patients (Crohn's, UC, other) receiving biologics or small molecules and tracked planned administrations between January and October 2024. Overall non-adherence was reported at 30.4% of patients and 12% of planned doses; missed doses were more common with subcutaneous and oral therapies than with intravenous infusions.
The authors found that receiving subcutaneous therapy and having a higher education level were independent predictors of non-adherence. Intravenous therapies (like infliximab) had fewer missed administrations in this cohort.
The report focuses on adherence measurement methods (infusion records, phone contact for subcutaneous patients, pill counts for oral agents) and compares rates across drug types without presenting intervention to improve adherence.
Keep In Mind
This is an abstract-level report of an observational study using administrative records, phone contact, and pill counts over a defined 10-month window in 2024. Differences in health systems, local infusion access, and measurement methods can affect adherence estimates. The study identifies associations, not causal effects.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
AuthorsDe Cristofaro Elena, Basile Luca, Zorzi Francesca +7 more
InstitutionGastroenterology Unit, Policlinico Universitario "Tor Vergata", Rome, Italy.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 9, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest EDC served as consultant for Abbvie; FZ served as consultant for Abbvie and receveid lecture fees from Abbvie and J&J; IM served as a consultant and speaker for Abbvie, Eli Lilly and Galapagos; GM served as a consultant for First Wave BioPharma, as a speaker for Takeda, AbbVie, Galapagos, and Pfizer, and filed a patent related to the treatment of inflammatory bowel diseases with Smad7 antisense oligonucleotides; EC served as advisory board member for Takeda, AbbVie and Johnson & Johnson and received lecture fees from AbbVie, Johnson & Johnson, Galapagos, Takeda, Ely Lilly. The other authors have no conflicts to disclose.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis.
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...